Global /United States /Healthcare /Biotechnology /TWST
chevron_leftBack
Twist Bioscience Corp. logo

Twist Bioscience Corp.

TWST
NASDAQ: TWST Delayed
56.70USD -4.1%
As of 8 June 2026, Twist Bioscience Corp. has a market cap of $3.48B USD, ranking #4918 globally and #1342 in the United States. It ranks #380 in the Healthcare sector, and #68 in the Biotechnology industry.
Global Rank
4918
Country Rank
1342
Sector Rank
380
Industry Rank
68
Key Stats
Market Cap
$3.48BUSD
Enterprise Value
$3.37BUSD
Revenue (TTM)
$391.56MUSD
EBITDA (TTM)
-$112.75MUSD
Net Income (TTM)
-$76.58MUSD
EBITDA Margin
-29%
Profit Margin
-20%
PS Ratio
8.8
PB Ratio
7.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Emily Leproust open_in_new
Employees
979
Founded
2013
IPO
31 Oct 2018
Website
twistbioscience.com open_in_new
1d 1w 1m 3m 6m 1y
-4.1% -9.5% 27% 35% 69% 42%

News

Loading...

TWST Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
TWST
Twist Bioscience Corp
ISIN: US90184D1000
Shares Out.:
62.271M1 Shares Float: 59.589M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
56.70 USD
Borsa Italiana
MIC: XMIL
1TWST
Twist Bioscience Corp
ISIN: US90184D1000
TV:
SA:
YF:
GF:
BA:
MS:
50.68 EUR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Twist Bioscience Corp.

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Similar Companies

Industry: Biotechnology (United States)
Name
Market Cap diff.
PE
AMGN
$182.42B
5K%
23.9
GILD
$159.92B
5K%
19.0
NTRA
$27.6B
694%
-
$26.3B
656%
20.0
$25.03B
620%
20.4
MRNA
$18.13B
422%
-
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
ARGX
$48.08B
41.39B EUR
1K%
39.9
$44.48B
68.19T KRW
1K%
35.5
LONN
$42.72B
33.71B CHF
1K%
37.2
CSL
$42.5B
60.27B AUD
1K%
29.3
068270
$27.89B
42.76T KRW
702%
43.8
BNTX
$25.69B
639%
-
chevron_leftBack